RedHill Biopharma (RDHL) Inventory Average (2017 - 2025)

RedHill Biopharma (RDHL) has reported Inventory Average for 9 consecutive years, with $3.4 million the latest figure, recorded in Q2 2025.

• On a quarterly basis, Inventory Average fell 16.76% year-over-year to $3.4 million in Q2 2025; TTM through Jun 2025 was $3.4 million, a 16.76% decrease from a year earlier, with the FY2024 full-year figure at $4.0 million, down 47.79% from the prior year.
• Inventory Average was $3.4 million for Q2 2025 at RedHill Biopharma, down from $3.7 million in the prior quarter.
• Over five years, Inventory Average peaked at $14.5 million in Q1 2022 and troughed at $3.4 million in Q2 2025.
• A 5-year average of $8.8 million and a median of $8.7 million in 2021 frame the typical range for Inventory Average.
• Across the five-year window, Inventory Average soared 239.77% in 2021 and plunged 60.46% in 2023, its largest moves.
• Over 5 years, Inventory Average stood at $14.0 million in 2021, then dropped by 15.51% to $11.8 million in 2022, then sank by 60.46% to $4.7 million in 2023, then retreated by 20.08% to $3.7 million in 2024, then retreated by 8.52% to $3.4 million in 2025.
• The last three Inventory Average figures came in at $3.4 million (Q2 2025), $3.7 million (Q4 2024), and $4.1 million (Q2 2024), per Business Quant data.